Glox Therapeutics is a developer of precision antibiotic therapies based on naturally occurring bacteriocins. Here are details of Glox Therapeutics‘ latest funding round :
Launch
2023 (February)
Industry
Biotechnology
Management
Dr. James Clark (CEO)
Funding & Investors
| INVESTMENT (Novembre 2023) | £4.3 million (Seed) |
| INVESTORS (Novembre 2023) | led by Boehringer Ingelheim Venture Fund and Scottish Enterprise. |
Funding purpose
Develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria, to establish laboratories in Oxford and Glasgow, and expand its team to accelerate its bacteriocin development program.
Country HQ
Scotland (Glasgow)